

## **EUROZ HARTLEYS HEALTHCARE CONFERENCE PRESENTATION**

**PERTH, Australia and SAN FRANCISCO, California – 6 February 2024**

PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC's CEO, Dr Rohan Hockings, at the Euroz Hartleys Healthcare Conference, 6 February 2024.

### **About PYC Therapeutics**

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**<sup>1</sup>.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood (RP11) into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#).

### **Forward looking statements**

*Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.*

---

2. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank  
<https://doi.org/10.1101/2020.11.02.2022232>

*This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.*

*This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited*

**CONTACTS:**

**INVESTORS and MEDIA**

[info@pyctx.com](mailto:info@pyctx.com)



**PYC**  
Therapeutics

Life-changing science

Euroz-Hartleys Healthcare Conference

February 2024



# Disclaimer

---



The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other

factors, many of which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

# Today's topics

- Introduction to PYC
- PYC's drug candidates are effective in patient-derived models
- Patient-derived models are the best predictor of success in human trials
- PYC is now in human trials establishing both safety and efficacy
- Success in these human studies will see PYC launch first-in-class drugs into market in 2028<sup>1</sup>

# PYC Therapeutics

- PYC is a precision medicine company progressing a pipeline of best-in-class drug candidates towards major unmet patient needs
- Each drug candidate represents a significant commercial opportunity
- In 2024, PYC will begin to generate the human safety and efficacy data critical to defining both the patient-impact and commercial success of this pipeline

# PYC has multiple assets progressing towards major unmet patient needs



‘Mini-organs’ (‘organoids’) derived from patients provide the greatest insight into outcomes in clinical trials

“We need to understand as early as possible whether a drug candidate is safe and works in patients, not wait to find out in clinical trials which can be expensive and time-consuming”

“I’m convinced that one can implement human organoids at every step of the way”


Hans Clevers - Head of Pharma Research and Early Development, Roche




# PYC's polycystic kidney disease drug candidate is effective in 3D kidney models derived from patients with end-stage renal failure

## 3D kidney model


### Polycystic kidney



### Untreated



### PYC-003 treated




### Unaffected kidney




# PYC's first blinding eye disease drug has demonstrated efficacy in 'retina-in-a-dish' models derived from patients with the disease


**Unaffected retina**



**Retinitis Pigmentosa (RP)**



**RP + VP-001 treatment**







# PYC's second blinding eye disease drug has demonstrated efficacy in 'retina-in-a-dish' models derived from patients with the disease


## Untreated

## PYC-001 treated

Fragmented mitochondria in ADOA patient retinal cells



Elongated mitochondria in ADOA patient retinal cells treated with PYC-001



# Success in the on-going human trials will see PYC launch multiple best-in-class drugs beginning in 2028

Indication	Market size <sup>1</sup>	Commercialisation <sup>2</sup>		
		2028	2029	2030
Retinitis Pigmentosa 11	\$1 billion p.a.	✓	✓	✓
Polycystic Kidney Disease	\$10 billion p.a.		✓	✓
Optic Atrophy	\$2 billion p.a.		✓	✓